Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Xanomeline-trospium chloride demonstrated significant efficacy for positive symptoms of schizophrenia in comparison to placebo in phase II and III trials. Other drugs such as ulotaront, vabicaserin, bitopertin, estradiol, cannabidiol, rimonabant, and D-serine were also noted to be effective for positive symptoms.
• For negative symptoms, roluperidone and pimavanserin showed effectiveness, while xanomeline-trospium chloride was not mentioned for this outcome. Cognitive function was improved by encenicline, tropisetron, pregnenolone, tolcapone, BI 425809, and valacyclovir, but not by xanomeline-trospium chloride.
• No significant differences in effectiveness were mentioned across different population types or subgroups.
• Xanomeline-trospium chloride (KarXT) demonstrates good short-term tolerability based on available trial data.
• No specific safety outcomes, adverse effects, or significant safety concerns are mentioned for xanomeline-trospium chloride in the reviewed studies.
• There is no population type or subgroup information available in the reviewed studies.